Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
62 hedge funds and large institutions have $130M invested in Stemline Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.
3,671% more call options, than puts
Call options by funds: $264K | Put options by funds: $7K
46% more capital invested
Capital invested by funds: $88.9M → $130M (+$41.1M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
2% more funds holding
Funds holding: 61 → 62 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
+$4.12M |
| 2 |
Goldman Sachs
New York
|
+$2.67M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.16M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$924K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$801K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.12M |
| 2 |
VAM
Visium Asset Management
New York
|
-$1.87M |
| 3 |
Renaissance Technologies
New York
|
-$1.24M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$932K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$679K |
STML Hedge Fund Activity: Q4 2014 in Review
62 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2014, worth a combined $130M — up 46% from $88.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new STML positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was VHCP Management, adding an estimated $4.12M. The largest seller was Artal Group, exiting entirely with an estimated $2.12M sold.
- 62 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2014, up from 61 in Q3 2014.
- Funds reported $130M of Stemline Therapeutics, Inc. stock for Q4 2014, up 46% quarter-over-quarter.
- 11 funds opened new Stemline Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +3 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2014 was VHCP Management, an estimated $4.12M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2014 was Artal Group, an estimated $2.12M sold.
Based on aggregated 13F filings for Q4 2014.